ClinicalTrials.gg
CompletedNCT01234259Updated Apr 16, 2020

Evaluation of Safety and Efficacy of Using Venus Freeze™ (MP)2 V2 System for Wrinkles Rhytides and Cellulite Treatment

An interventional study of Venus Freeze (MP2 V2 System in Wrinkled Structure and Circumference Reduction, sponsored by Venus Concept. Completed at 1 site in Israel. Open to participants aged 30 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-16.

Sponsored by Venus Concept · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Study summary

Skin aging is a multifactorial process involving the 3 layers of the skin: Epidermis, dermis and hypodermis.

Radio-frequency (RF) devices have been used for many years for a variety of surgical applications. The energy delivery systems of these established monopolar devices used a 'conductive coupling' delivery system in which energy is concentrated at the periphery of the electrode.

Venus Concept has developed the Venus Freeze (MP)2 V2 system for wrinkles, rhytides and temporary cellulite and circumference reduction treatments. While treating wrinkles rhytides and cellulite, the treatments creates enough thermal effect to induce collagen remodeling with no ablative thermal damage in the epidermis or dermis.

02

Conditions studied

  • Wrinkled Structure
  • Circumference Reduction

Browse trials for

Keywords

  • Wrinkles
  • rhytides
  • Cellulite
  • circumference reduction
03

In context

Cellulite

71 studies on the registry are indexed under Cellulite; 3 are open to participants now.

This study's enrollment of 60 is above the median of 34 across 65 interventional studies indexed under Cellulite.

Browse Cellulite studies →

Lead sponsor

Venus Concept is the lead sponsor of 34 studies on the registry; 4 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 12 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males and females age 30 and up
  • Subjects with Fitzpatrick 4 to 9 degrees of elastosis
  • Subject able to comprehend and give for participation in this study
  • Subject must commit to all treatments and follow-up visits
  • Subject must sign the Informed Consent Form

Exclusion criteria

Exclusion Criteria:

  • Subjects with implanted pacemakers, arrhythmias or any other severe known heart disorder
  • Subjects with any implantable metal device in the treatment area
  • Subjects on any medication that would affect the characteristic of the skin (medical or hormonal), such as "Accutane", within the past 6 months or photosensitizing medications
  • Subjects that have had any other invasive or non invasive method of skin therapy or hair removal performed in the past 9 months (in the treated area) Subjects who are scheduled or planned for any other invasive or non invasive method of skin therapy or hair removal in the treated area at the period of the study
  • Subjects who have any form of malignant skin cancer on the treatment area
  • Subjects with history of keloid formations or hypertrophic scarring
  • Pregnant or lactating Subjects
  • Subjects with Epilepsy or severe migraines
  • Subjects with permanent makeup/ tattoo/ body piercing (in the treated area)
  • Subjects with any Infection / abscess / dermatitis/ pains in treatment target area.
  • Subjects who suffer from disorders or diabetes
  • Subjects with clotting disorders
  • Subjects are suffering from psychiatric disorders and treated with psychiatric medications.
  • Subject is suffering extreme general weakness.
  • Subject objects to the study protocol
  • Concurrent participation in any other clinical study
  • Physician objection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Study group

    Device: Venus Freeze (MP)2 V2 system

    Device: Venus Freeze (MP2 V2 System

  • Sham comparator
    control group:

    Sham comparator

    Device: Venus Freeze (MP2 V2 System

Interventions

  • DeviceVenus Freeze (MP2 V2 System

    Facial wrinkles and temporary cellulite and circumference reduction treatments

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of the Venus system for wrinkles rhytides and temporary cellulite and circumference reduction treatment. Efficacy evaluation will include RF, Magnetic Pulse Field and vacuum technology.

    Efficacy will be established by skin improvement as a result of the treatment by validated scales. Results will be compared to control group results. The pre - and post-treatment photographs will be compared and assessed by three independent dermatologists.

    Time frame: 5 months

Secondary outcomes

  1. To evaluate the safety of the Venus Freeze (MP)2 V2 system for wrinkles, rhytides, temporary cellulite and circumference reduction. Safety evaluation will include RF, Magnetic Pulse Field and vacuum technology.

    Safety parameters will include adverse events (signs of pain; edema; burn; localized infection; skin pigmentation \& texture alterations) occurring as a direct result of the treatment and complaints up to last follow up visit.

    Time frame: 5 months

07

Study locations

1 site
  • Sourasky medical Centre
    Tel-Aviv, 64239, Israel
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2010
First posted
Nov 4, 2010
Start
Dec 2010
Primary completionActual
Sep 2014
CompletionActual
Sep 2014
Last update
Apr 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01234259
Lead sponsor
Venus Concept
Responsible party
Sponsor
First posted
Nov 4, 2010
Start date
Dec 2010
Primary completion
Sep 2014
Completion
Sep 2014
Last update
Apr 16, 2020

Study contacts

Eli Sprecher, Prof.
principal investigator · Tel-Aviv Sourasky medical Centre, Israel

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion